95. Modality convergence in advanced therapies
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
95. Modality convergence in advanced therapies
-
Narrated by:
-
By:
About this listen
Join us in this lite bite episode as Dr. Aravind Asokan, Duke University, explores cutting-edge technologies revolutionizing advanced therapies, including CRISPR, mRNA, viral vectors, and cell therapies. He shares key lessons from past challenges, discusses scalability, product quality, and how integrating various therapeutic approaches is shaping the future of disease treatment.
This episode covers exciting advancements in AAV with CRISPR, CAR T cell therapy, circular RNA, and virus-like particles (VLPs).
Show notes
Asokan A, et al. ‘An evolved AAV variant enables efficient genetic engineering of murine T cells’. Cell. 2023 Jan 19;186(2):446-460. https://doi.org/10.1016/j.cell.2022.12.022
adbl_web_global_use_to_activate_webcro805_stickypopup
No reviews yet